IT之家 · 智能时代 · 10/8/2026, 14:33:15
Isomorphic Labs Seeks Funding at $40-50 Billion Valuation Amid AI Drug Discovery Boom
Isomorphic Labs, the Alphabet subsidiary led by Nobel laureate Demis Hassabis, is in early talks for a new funding round targeting a valuation of $40-50 billion. Following a $2.1 billion Series B in May 2024, this significant valuation jump highlights intense investor confidence in AI-driven drug discovery, although the sector remains in its early stages prior to widespread clinical trial success.
SOURCE COVERAGEOriginal coverage
On October 8, Bloomberg reported that Isomorphic Labs, the Alphabet subsidiary focused on AI-driven drug discovery led by Demis Hassabis (the 2024 Nobel Prize in Chemistry laureate), is in early-stage negotiations for a new funding round.
Isomorphic Labs completed its Series B financing in May of this year, raising $2.1 billion from investors including its parent company (Note: equivalent to approximately RMB 14.096 billion at current exchange rates).
The report indicates that the company’s valuation in this new round is at least 50 billion (approximately RMB 335.623 billion).
The application of artificial intelligence in biopharmaceuticals remains in its early stages. Although multiple industry players have conducted various explorations at the conceptual level, significant efforts are still required to bridge the gap through clinical trials and toward final market approval.